Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
It seems few can resist the revenue that can await a cancer treatment.
After over a decade extending the half-life of medicines for J&J, Genentech and other large players, Amunix is pivoting to develop elements of its platform into two approaches to immuno-oncology, one of which is an off-the-shelf alternative to CAR–T treatments. And they’re licensing a portion of the older technology to Roche for $40 million and $1.5 billion in potential milestones.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters